News & Updates
Filter by Specialty:
Are SGLT2 inhibitors cardioprotective in wild-type ATTR-CM patients?
The use of sodium glucose cotransporter-2 (SGLT2) inhibitors nearly halves the risk of all-cause mortality at 3 years in patients with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) and type 2 diabetes (T2D), findings from an observational study suggest.
Are SGLT2 inhibitors cardioprotective in wild-type ATTR-CM patients?
05 Nov 2024
RSV may worsen clinical outcomes in HF patients
A retrospective analysis presented at HSFA ASM 2024 shows that respiratory syncytial virus (RSV) infection in individuals with heart failure (HF) is associated with greater adverse clinical outcomes.
RSV may worsen clinical outcomes in HF patients
01 Nov 2024
Sacubitril/valsartan maintains efficacy, safety in HF patients with hypotension
Both symptomatic and asymptomatic hypotension are associated with worse outcomes during treatment with either enalapril or sacubitril/valsartan, but the benefits derived from the combination therapy are maintained or even improved in heart failure (HF) patients with hypotension, a study has shown.
Sacubitril/valsartan maintains efficacy, safety in HF patients with hypotension
31 Oct 2024
Aficamten improves clinical outcomes in obstructive HCM
Patients with obstructive hypertrophic cardiomyopathy (oHCM) can derive broad clinical benefits from treatment with aficamten, which include complete haemodynamic response and improved exercise capacity among others, as shown by the results of the SEQUOIA-HCM study.